KLRS Earnings — Kalaris Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
KLRS — Kalaris Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$5.27
Market Cap$125.4M
P/E—
52W Range$2.14 – $11.88
Next Earnings2026-08-12
About Kalaris Therapeutics, Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
